Aardvark Therapeutics, Inc. Insider Trading

AARD

⊜ Compare

Last 12 months

Insiders bought 145K and sold 395K on the open market.

All of the selling was scheduled in advance under 10b5-1 plans.

Net open-market

−250K

2 buys · 1 sale

Under a 10b5-1 plan

100%

of the value sold

Insiders who bought / sold

2 / 1

executives and directors

Last open-market buy

Dec 2025

Dec 11, 2025

Get an email when AARD's executives or directors buy, or make a large sale outside a plan.

Trades · last 2 years

Date	Insider	Trade	Shares	Price	Value	Of their stake	Filing
Sep 10 – 11	Nelson Sun See Remarks	Sold10b5-1 plan 2 parts	76,754	$5.15 average	395K	68%	Form 4
Dec 11, 2025	Nelson Sun Chief Financial Officer	Bought	3,000	$14.40	43K	2.8%	Form 4
Dec 11, 2025	Tien-Li Lee Chief Executive Officer	Bought	7,000	$14.49	101K	0.2%	Form 4
Sep 15, 2025	Tien-Li Lee Chief Executive Officer	Bought 2 parts	10,000	$9.66 average	97K	0.3%	Form 4
Sep 10, 2025 – Sep 12, 2025	Tien-Li Lee Chief Executive Officer	Bought 3 parts	20,000	$8.03 average	161K	0.7%	Form 4
Sep 9, 2025	Nelson Sun Chief Financial Officer	Bought	6,000	$8.07	48K	6.0%	Form 4
Feb 14, 2025	Decheng Capital Global Life Sciences Fund IV, L.p. Large holder	Bought 2 parts	1,250,000	$16.00 average	$20M	47%	Form 4
Feb 14, 2025	Tien-Li Lee Chief Executive Officer	Bought	16,542	$16.00	265K	0.6%	Form 4
Feb 14, 2025	Nelson Sun Chief Financial Officer	Bought	10,000	$16.00	160K	11%	Form 4
Feb 14, 2025	Bihua Chen Other	Bought	187,500	$16.00	$3M	23%	Form 4

Sep 10 – 1110b5-1 plan
Nelson Sun
See Remarks · sold 76,754 at avg $5.15
395K
68% of stake
Dec 11, 2025
Nelson Sun
Chief Financial Officer · bought 3,000 at $14.40
43K
2.8% of stake
Dec 11, 2025
Tien-Li Lee
Chief Executive Officer · bought 7,000 at $14.49
101K
0.2% of stake
Sep 15, 2025
Tien-Li Lee
Chief Executive Officer · bought 10,000 at avg $9.66
97K
0.3% of stake
Sep 10, 2025 – Sep 12, 2025
Tien-Li Lee
Chief Executive Officer · bought 20,000 at avg $8.03
161K
0.7% of stake
Sep 9, 2025
Nelson Sun
Chief Financial Officer · bought 6,000 at $8.07
48K
6.0% of stake
Feb 14, 2025
Decheng Capital Global Life Sciences Fund IV, L.p.
Large holder · bought 1,250,000 at avg $16.00
$20M
47% of stake
Feb 14, 2025
Tien-Li Lee
Chief Executive Officer · bought 16,542 at $16.00
265K
0.6% of stake
Feb 14, 2025
Nelson Sun
Chief Financial Officer · bought 10,000 at $16.00
160K
11% of stake
Feb 14, 2025
Bihua Chen
Other · bought 187,500 at $16.00
$3M
23% of stake

How to read this. Insiders sell for many reasons: taxes, diversifying, a house. Open-market buys are rarer and say more. A 10b5-1 plan is a trading schedule set up months in advance, so those sales were not timed on news. Large holders (funds and 10% owners) are listed under Everything but not counted as insiders. If you own or watch AARD, we send a push when an executive buys or makes a large sale outside a plan.

Source: SEC Form 4 filings, filed within two business days of each trade and checked for new ones every hour.

Peers

Pharmaceutical Preparations · Pick stocks to compare with AARD

CompareIntrinsic value

ORMPOramed Pharmaceuticals Inc.

$4.11-2.84%35

NTHINeonC Technologies Holdings

$3.26+4.49%10

SLNSilence Therapeutics plc

$19.75-0.25%10

SEPNSepterna, Inc.

$43.97-2.79%48

AXSMAxsome Therapeutics, Inc.

$144.01+0.39%10

NKTXNkarta Inc.

$1.56-6.02%10

TNXPTonix Pharmaceuticals Holding Corp

$5.09-3.60%40

SCYXScynexis, Inc.

$3.72-3.63%40

Held by ETFs

AARD is in 4 US ETFs. The largest of them, with AARD's weight in each:

Spot a number that looks wrong? Check it in AARD's SEC filings or

Download this analysis as a PDF (Pro)

Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

2 of 2 free stocks used today

Keep analysing AARD

Create a free account and get 14 days of Premium: every stock and every tool.

Unlimited stocksQuality, fair value and dividends for 10,000+ stocks
Stock screenerFilter on quality, valuation and dividend safety
Portfolio trackerReal return, dividend calendar and portfolio quality
Editable DCFChange the assumptions and watch fair value move
Compare side by sideUp to 10 stocks in one table
Unlimited alertsPrice, P/E, Quality Score and yield

No card. Moves to Free after, unless you upgrade.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.